insights_auto
Why is 2359 down 2,19%?
Dive Deeperchevron_right
2359:HKG
WuXi AppTec Ord Shs H
196,20 HK$
arrow_downward
-2,19%(-4,40) 1D
16 հոկ, 16:08:14 GMT+8 · HKD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 2359...
Open
203,80 HK$
High
209,00 HK$
Low
185,00 HK$
Mkt. cap
544,52 մլրդ
Avg. vol.
3,91 մլն
Volume
10,16 մլն
Dividend
1,22%
Quarterly dividend
0,60 HK$
Ex-dividend date
04 սեպ, 2026 թ.
P/E ratio
23,98
52-wk high
219,20 HK$
52-wk low
96,70 HK$
EPS
8,18 HK$
No. of employees
36 հզր
Open
203,80 HK$
High
209,00 HK$
Low
185,00 HK$
Mkt. cap
544,52 մլրդ
Avg. vol.
3,91 մլն
Volume
10,16 մլն
Dividend
1,22%
Quarterly dividend
0,60 HK$
Ex-dividend date
04 սեպ, 2026 թ.
P/E ratio
23,98
52-wk high
219,20 HK$
52-wk low
96,70 HK$
EPS
8,18 HK$
No. of employees
36 հզր
News stories
From web sources and news partners
ad-hoc-news.de
·
4 ժամ առաջ
Simply Wall St cuts target for WuXi AppTec stock to CNY 224.81
ad-hoc-news.de
·
5 ժամ առաջ
WuXi AppTec stock at EUR 22.03 ahead of the Xetra open: CRDMO group
ad-hoc-news.de
·
20 ժամ առաջ
WuXi AppTec earns EcoVadis gold: what it means for WuXi AppTec stock
Profile
WuXi AppTec Co., Ltd. is a Chinese provider of contract research, development, and manufacturing, services for the pharmaceutical and life-sciences industry, headquartered in Shanghai, China. The company operates research and manufacturing facilities in Asia, North America, and Europe.
Founded in 2000 by chemist Ge Li as WuXi PharmaTech, the company expanded through acquisitions and re‑listings in 2018 after a 2015 take‑private. It produces a large part of the ingredients used in treatments for illnesses including leukemia, lymphoma, HIV, and obesity. As of 2025, the company reported around 39,000 employees and 6,000 customers. Its clients have included Jiangsu Hengrui, GlaxoSmithKline, AstraZeneca and Pfizer. Wikipedia
About WuXi AppTec Ord Shs H
CEOSteve Yang | Ge Li
Employees35,6 հզր
Founded01 դեկ, 2000 թ.
Headquarters-
Sector-
Websitewuxiapptec.com.cn